Renagel and Repaglinide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Renagel (sevelamer hydrochloride) and Repaglinide (repaglinide). Common drug interactions include pulmonary embolism among females and alanine aminotransferase increased among males.

The phase IV clinical study analyzes what interactions people have when they take Renagel and Repaglinide. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Renagel?

Renagel has active ingredients of sevelamer hydrochloride. eHealthMe is studying from 8,246 Renagel users. Check the latest studies of Renagel.

What is Repaglinide?

Repaglinide has active ingredients of repaglinide. It is often used in diabetes. eHealthMe is studying from 8,226 Repaglinide users. Check the latest studies of Repaglinide.



On Jul, 31, 2026

22 people who take Renagel and Repaglinide together, and have interactions are studied.

Renagel and Repaglinide drug interactions.

What are the common drug interactions of Renagel and Repaglinide, by gender? *:

female:

  1. Pulmonary embolism (blockage of the main artery of the lung)
  2. Diarrhoea
  3. Hypotension (abnormally low blood pressure)
  4. Anaemia (lack of blood)
  5. Cardiac failure congestive
  6. Cardiopulmonary failure (cessation of normal circulation of the blood due to failure of the heart to contract)
  7. Circulatory collapse
  8. Nausea (feeling of having an urge to vomit)
  9. Pneumonia
  10. Renal failure chronic (long lasting kidney dysfunction)

male:

  1. Alanine aminotransferase increased
  2. Aspartate aminotransferase increased
  3. Abdominal distension
  4. Abdominal pain
  5. Anaemia (lack of blood)
  6. Angioplasty
  7. Asthenia (weakness)
  8. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  9. Blood creatinine increased
  10. Blood pressure increased

What are the common drug interactions of Renagel and Repaglinide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Abdominal distension
  2. Abdominal pain
  3. Arrhythmia (irregular heartbeat)
  4. Asthenia (weakness)
  5. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  6. Blood creatinine increased
  7. Blood pressure increased
  8. Cardiomegaly (increased size of heart than normal)
  9. Constipation
  10. Diarrhoea

50-59:

  1. Circulatory collapse
  2. Anaemia (lack of blood)
  3. Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
  4. Dizziness
  5. Hydrocephalus (water on the brain)
  6. Leukocytoclastic vasculitis (inflammation of small blood vessels (usually post-capillary venules in the dermis), characterized by palpable purpura)
  7. Nephropathy (damage to or disease of a kidney)
  8. Renal impairment (severely reduced kidney function)
  9. Sepsis (a severe blood infection that can lead to organ failure and death)
  10. Thrombocytopenia (decrease of platelets in blood)

60+:

  1. Pulmonary embolism (blockage of the main artery of the lung)
  2. Alanine aminotransferase increased
  3. Dysphagia (a condition in which swallowing is difficult or painful)
  4. Myalgia (muscle pain)
  5. Nausea (feeling of having an urge to vomit)
  6. Pneumonia
  7. Polymyositis (inflammatory muscle disease that causes weakness of the skeletal muscles)
  8. Renal failure acute (rapid kidney dysfunction)
  9. Renal failure chronic (long lasting kidney dysfunction)
  10. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)

What are the existing conditions these people have? *

  1. Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 2 people, 9.09%
  2. Pain: 2 people, 9.09%
  3. Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Renagel and Repaglinide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Renagel and Repaglinide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Renagel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Repaglinide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Renagel and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Repaglinide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on sevelamer hydrochloride and repaglinide (the active ingredients of Renagel and Repaglinide, respectively), and Renagel and Repaglinide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: